Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors after Treatment with [177Lu-DOTA0,Tyr3]Octreotate Abstract #667

Introduction: Response Evaluation Criteria in Solid Tumors (RECIST) (unidimensional), Southwest Oncology Group (SWOG) solid tumor response criteria (bidimensional), and their modified variants (mRECIST/mSWOG) are used to assess treatment response in gastroenteropancreatic and thoracic neuroendocrine tumors (NETs).
Aim(s): To compare the RECIST, SWOG, mRECIST and mSWOG criteria in NET patients treated with [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate).
Materials and methods: CT/MRI scans of 268 NET patients, treated with 177Lu-octreotate, were analyzed using RECIST, SWOG, mRECIST and mSWOG criteria (including the response class minor response (MR) (decrease of 13-30% for mRECIST and 25-50% for mSWOG)). The outcomes were correlated with overall survival (OS).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Esther I Van Vliet

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result